Zentalis Pharmaceuticals has dosed the first patient in the Phase 3 ASPENOVA trial, testing azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial compares azenosertib to standard chemotherapy and aims to confirm benefits seen in earlier Phase 2 studies, supporting full FDA approval. The ASPENOVA study enrolls about 420 patients globally and focuses on progression-free survival as the primary endpoint. Results from the ongoing Phase 2 DENALI trial, expected by the end of 2026, may lead to accelerated approval, while ASPENOVA will provide confirmatory data for full approval.
Aduro Clean Technologies Inc., a cleantech company specializing in converting low-quality materials into valuable resources, has received final approval to list its common shares on the Toronto Stock Exchange (TSX) under the ticker "ACT" starting May...
Aduro Clean Technologies, a clean tech company specializing in chemical recycling of low-value raw materials, has received final approval to list its common shares on the Toronto Stock Exchange (TSX) under the symbol ACT starting May 27, 2026. Concur...
The 2026 China (Jinhua Mountain) International Camping Congress was held from May 16-17 in Zhejiang Province, focusing on integrating culture, sports, tourism, and industry to develop camping tourism and leisure. The event attracted around 200 guests...
The Schall Law Firm is investigating UP Fintech Holding Limited for possible securities law violations after a Reuters report revealed China's crackdown on illegal cross-border securities trading. The report accused UP Fintech's Tiger subsidiary of o...
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
